- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | AEON Biopharma, Inc. - 8-K, Current Report | - | SEC Filings | ||
| AEON BIOPHARMA Aktie jetzt für 0€ handeln | |||||
| 23.10. | AEON Biopharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 09.10. | AEON Biopharma Inc: AEON Biopharma Reports Inducement Grant Under NYSE American LLC Company Guide Section 711 | 1 | GlobeNewswire (USA) | ||
| 30.09. | AEON Biopharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 09.09. | Laidlaw stuft Aeon Biopharma mit "Buy" ein: Aktie mit erheblichem Kurspotenzial | 2 | Investing.com Deutsch | ||
| 09.09. | Laidlaw initiates Aeon Biopharma stock coverage with buy rating | 4 | Investing.com | ||
| 24.08. | AEON Biopharma Inc: AEON Biopharma Designates Former FDA Neuroscience Leader Paul Lee, M.D., Ph.D. as Acting Chief Regulatory Officer | 482 | GlobeNewswire (Europe) | - Former Deputy Director of the FDA's Office of Neuroscience - Dr. Lee has previously advised AEON through Clintrex Research LLC (Clintrex), an affiliate of BlueRidge Life Sciences, on the regulatory... ► Artikel lesen | |
| 19.08. | AEON Biopharma Inc: AEON Reports Expanded Structural Data Supporting Molecular Similarity of ABP-450 to BOTOX | 523 | GlobeNewswire (Europe) | - Complementary peptide-mapping methods increased coverage of the active botulinum neurotoxin primary sequence from approximately 93% to 98%, with 100% amino acid identity across all regions analyzed... ► Artikel lesen | |
| 17.08. | H.C. Wainwright senkt Kursziel für Aeon Biopharma Aktie wegen Verwässerung | 1 | Investing.com Deutsch | ||
| 17.08. | H.C. Wainwright cuts Aeon Biopharma stock price target on dilution | 2 | Investing.com | ||
| 13.08. | AEON Biopharma Q2 Non-GAAP EPS of -$0.02 | 1 | Seeking Alpha | ||
| 12.08. | AEON Biopharma Inc: AEON Biopharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update | 260 | GlobeNewswire (Europe) | - Executed a $15.3 million financing with milestone warrants providing potential for an additional $34.0 million in gross proceeds, supporting continued advancement of ABP-450's development program... ► Artikel lesen | |
| 12.08. | AEON Biopharma, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 12.08. | AEON Biopharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 03.08. | AEON Biopharma regains NYSE American listing compliance after $13.6M offering | 1 | Seeking Alpha | ||
| 03.08. | AEON Biopharma Inc: AEON Biopharma Regains Compliance with NYSE American Continued Listing Standards | 174 | GlobeNewswire (Europe) | ALISO VIEJO, Calif., Aug. 03, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 as a biosimilar to BOTOX... ► Artikel lesen | |
| 23.07. | AEON Biopharma, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 15.07. | AEON Biopharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 14.07. | AEON Biopharma prices $13.75M offering with milestone warrants | 1 | Seeking Alpha | ||
| 14.07. | AEON Biopharma Inc: AEON Biopharma Announces Pricing of Upsized $13.75 Million Public Offering with Accompanying Milestone Warrants Providing Potential for Additional Future Funding | 265 | GlobeNewswire (Europe) | IRVINE, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 as a biosimilar to BOTOX® (onabotulinumtoxinA)... ► Artikel lesen |
1 2 Weiter >>
34 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIOFRONTERA | 3,060 | +2,00 % | Dermatology with Tailwinds: How Galderma Is Deploying Billions, Vidac Pharma Awaits Crucial Clinical Data and Biofrontera Expands | ||
| TEMPUS AI | 68,40 | -1,51 % | Ihre wichtigsten Termine: Frische Q-Zahlen von Apple, Palantir, BioMarin, Marriott International, Fox Corp | © Foto: Andrej Sokolow - dpaGut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag Enthaltene Werte: US0378331005... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,210 | -9,87 % | Defence Therapeutics Inc.: Defence Therapeutics Announces Convertible Debenture Interest Payment | Montreal, Quebec--(Newsfile Corp. - October 23, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology company developing... ► Artikel lesen | |
| ABIVAX | 80,40 | +1,64 % | EQS-News: ABIVAX: Abivax to Participate in Upcoming Fall Investor Conferences | EQS-News: ABIVAX
/ Key word(s): Conference
Abivax to Participate in Upcoming Fall Investor Conferences
02.11.2026 / 22:05 CET/CEST
The issuer is solely responsible for... ► Artikel lesen | |
| TRAWS PHARMA | 0,304 | +0,66 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 02.10.2026 -4- | The following instruments on Boerse Frankfurt do have their last trading day on 02.10.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 02.10.2026ISIN NameUS1509643029 CENNTRO... ► Artikel lesen | |
| CURIS | 0,920 | +48,12 % | Curis, Inc. Announces Pricing of $5.6 Million Public Offering | LEXINGTON, Mass., Aug. 13, 2026 /PRNewswire/ -- Curis, Inc. (Nasdaq: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally... ► Artikel lesen | |
| GENPREX | 2,285 | -1,08 % | Genprex, Inc. - 8-K, Current Report | ||
| TVARDI THERAPEUTICS | 0,765 | +4,79 % | Tvardi Therapeutics Announces Second Quarter 2026 Results and Provides Business Update | Reported topline healthy volunteer results for next-generation STAT3 inhibitor TTI-109, confirming the prodrug design, improved tolerability and reductions in disease-relevant immune cell populations... ► Artikel lesen | |
| NEOVACS | 0,002 | -95,00 % | XFRA CAPITAL ADJUSTMENT INFORMATION - 22.10.2026 | Das Instrument 1DD FR001400H2X4 TONNER DRON. S.A.EO-,0001 EQUITY wird ex Kapitalmassnahme gehandelt am 22.10.2026 The instrument 1DD FR001400H2X4 TONNER DRON. S.A.EO-,0001 EQUITY is traded ex capital... ► Artikel lesen | |
| ALAUNOS THERAPEUTICS | 1,830 | -1,61 % | Paragon Labs Adds Former Apogee Leaders As Alaunos Completes Velaris Acquisition; Stock Up | WASHINGTON (dpa-AFX) - Paragon Labs announced that several former senior executives from Apogee Therapeutics (APGE) have joined its leadership team, while Alaunos Therapeutics, Inc. (TCRT) completed... ► Artikel lesen | |
| ALTERITY THERAPEUTICS | 0,162 | +19,12 % | ALTERITY THERAPEUTICS LIMITED: Alterity Therapeutics Releases Appendix 4C - Q1 FY27 Quarterly Cash Flow Report & Corporate Update | ||
| MARKER THERAPEUTICS | 0,860 | +4,24 % | Marker Therapeutics sichert sich FDA-Förderung über 2,6 Millionen US-Dollar für Krebsstudie | ||
| AINOS | 0,620 | +0,05 % | Ainos, Inc.: Ainos Surpasses 3 Billion Real-World Chemical Data Points, Advancing Chemical Intelligence for Smart Factories | Chemical dataset surpasses 3 billion data points, more than tripling September milestoneFollowing delivery of 1,400 AI Nose systems, continued collaboration with a major semiconductor assembly and test... ► Artikel lesen | |
| MATINAS BIOPHARMA | 1,040 | 0,00 % | Matinas BioPharma Holdings, Inc. - 8-K, Current Report | ||
| ENVERIC BIOSCIENCES | 1,490 | -0,67 % | Enveric completes drug absorption studies for EB-003 candidate |
Das Unternehmen AEON BIOPHARMA INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,002 (+0,89 %) liegt der Kurs bei 0,215 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu AEON BIOPHARMA INC finden Sie auf Wallstreet Online.